4-Chloro-2-ethyl-1-methylbenzene | 89032-09-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Chloro-2-ethyl-1-methylbenzene
• CAS: 89032-09-7
• 化学式: C₉H₁₁Cl
• 分子量: 154.63
• InChiKey: FWBCOFWYTCTDLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  2,4-二氯甲苯 、 乙基溴化镁 以57%的产率得到
  参考文献：
  名称：

  REDDY, G. S.;TAM, W., ORGANOMETALLICS, 1984, 3, N 4, 630-632

  摘要：

  DOI：

文献信息

• Raf inhibitor compounds and methods of use thereof
  申请人：Miknis Greg

  公开号：US20070049603A1

  公开（公告）日：2007-03-01

  Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式I的化合物对抑制Raf激酶和治疗由此介导的疾病有用。公开了使用公式I的化合物及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• [EN] ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS<br/>[FR] ANILINOPYRIMIDINES EN TANT QU'INHIBITEURS DE KINASE 1 PROGÉNITRICES HÉMATOPOÏÉTIQUES (HPK1)
  申请人：ARIAD PHARMA INC

  公开号：WO2018102366A1

  公开（公告）日：2018-06-07

  The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.

  这项发明涉及用于治疗癌症和其他丝氨酸-苏氨酸激酶介导的疾病的HPK1抑制剂，其化学式为：其中A、R1、R2、R3、R4、R5、R6、R16、R17、X1、X2、X3、X4、m和n如本文所述。
• ANTI-ESTROGENIC COMPOUNDS
  申请人：PFIZER INC.

  公开号：US20160311805A1

  公开（公告）日：2016-10-27

  The present disclosure provides a compound of Formula I: or a pharmaceutically acceptable salt wherein X, R 1 -R 8 , Y 1 -Y 5 , m, n, p, and q are defined herein. The novel 2H-chromene compounds are useful for the modulation of disorders mediated by estrogen, and other disorders, as described herein. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions.

  本公开提供一种具有以下化学式的化合物：或其药用可接受盐，其中X、R1-R8、Y1-Y5、m、n、p和q在此处定义。这些新型2H-香豆素化合物对通过雌激素介导的疾病和其他疾病的调节具有用处，如本文所述。本发明还涉及含有这些化合物的药物组合物以及使用这些化合物和组合物的方法。
• TRICYCLIC GUANIDINE DERIVATIVE
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20160083400A1

  公开（公告）日：2016-03-24

  Disclosed are compounds useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.

  揭示了作为磷酸二酯酶1（PDE1）抑制剂有用的化合物，以及它们的组合物和使用方法。
• INDAZOLEPROPIONIC ACID AMIDE COMPOUND
  申请人：Yamaguchi Tetsuo

  公开号：US20120016117A1

  公开（公告）日：2012-01-19

  Disclosed is a compound which is useful in preventing and treating cardiac arrhythmia such as atrial fibrillation. A compound represented by formula (1) or a pharmaceutically acceptable salt of the same. In formula (1), ring X represents benzene or pyridine; R 1 represents an optionally substituted alkyl group; R 2 represents an optionally substituted aryl group, an optionally substituted heterocyclic group, an optionally substituted arylalkyl group or an optionally substituted heterocyclic group-substituted alkyl group; R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 represent each hydrogen or an alkyl group, provided that R 3 and R 5 may be bonded to each other to form, together with the carbon atom adjacent thereto, a cycloalkyl group; and m represents 0 or 1.

  本申请揭示了一种化合物，用于预防和治疗心律失常，如心房纤颤。该化合物由式（1）表示，或者其药学上可接受的盐。在式（1）中，环X代表苯或吡啶；R1代表可选择地取代的烷基基团；R2代表可选择地取代的芳基基团，可选择地取代的杂环基团，可选择地取代的芳基烷基基团或可选择地取代的杂环基团取代的烷基基团；R3、R4、R5、R6、R7、R8和R9分别代表氢或烷基基团，但R3和R5可以结合在一起，与相邻的碳原子一起形成环烷基基团；m代表0或1。